Key result
Pioglitazone reduces serum RBP4 and NF-κB activity in diabetic atherosclerotic rats.
Why the study?
This study was conducted to investigate the expression of retinol binding protein 4 (RBP4) and the activity of nuclear factor-kappa B (NF-κB) in diabetic rats with atherosclerosis, and to evaluate the intervention effect of pioglitazone.
Answers are grounded in this paper and cite their sources.
No practice change from animal data alone; leaves open whether pioglitazone improves human diabetic atherosclerosis outcomes.
This study aims to investigate the expression of retinol binding protein 4 (RBP4) and the activity of nuclear factor-kappa B (NF-κB) in diabetic rats with atherosclerosis, and to evaluate the intervention effect of pioglitazone. A total of 75 Wistar rats were randomly divided into four groups: Normal control (NC), diabetic rats (DM1), diabetic rats with atherosclerosis (DM2) and diabetic rats treated with pioglitazone (DM + Pio). The activity of NF-κB, the levels of serum and adipose tissue RBP4, fasting plasma glucose (FPG), fasting insulin (FINS), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG) and arteria caudilis systolic blood pressure (SBP) were measured. Percentage of fat mass (PFM), atherogenic index of plasma (AIP) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Compared with the NC and DM + Pio groups, all the parameters mentioned above increased significantly in the DM1 and DM2 groups, with the exception that HDL-c decreased. Pearson analysis showed that RBP4 in serum and adipose tissue were positively associated with TG, LDL-c, FINS, PFM, AIP, HOMA-IR, NF-κB, SBP and negatively associated with HDL-c. Multivariable logistic regression analysis showed that serum RBP4 and TG were predictors for the presence of diabetic atherosclerosis. In conclusion, RBP4 may be an effective predictor for diabetic atherosclerosis; pioglitazone is able to decrease RBP4 and NF-κB, which may partly contribute to its protective effect against diabetic atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2016) studied Diabetic atherosclerosis (rat model) (n=75). Pioglitazone vs. Sodium chloride vehicle in diabetic atherosclerosis rats (DM2) was evaluated on Serum retinol binding protein 4 (RBP4, ng/ml) and predictor of diabetic atherosclerosis (OR 1.409, 95% CI 1.188-2.035, p=<0.01). Pioglitazone significantly reduced serum RBP4 (31.03 vs 56.52 ng/ml, P<0.01) and NF-κB activity (0.73 vs 1.43, P<0.01) compared to untreated diabetic atherosclerotic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: